CN113607946B - Application of detecting transcription factor MAX gene expression quantity in liver cancer c-MYC targeted therapy prognosis evaluation kit - Google Patents
Application of detecting transcription factor MAX gene expression quantity in liver cancer c-MYC targeted therapy prognosis evaluation kit Download PDFInfo
- Publication number
- CN113607946B CN113607946B CN202110901877.8A CN202110901877A CN113607946B CN 113607946 B CN113607946 B CN 113607946B CN 202110901877 A CN202110901877 A CN 202110901877A CN 113607946 B CN113607946 B CN 113607946B
- Authority
- CN
- China
- Prior art keywords
- liver cancer
- transcription factor
- myc
- max gene
- targeted therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 54
- 101150018298 MAX gene Proteins 0.000 title claims abstract description 52
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 41
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 41
- 108091023040 Transcription factor Proteins 0.000 title claims abstract description 38
- 102000040945 Transcription factor Human genes 0.000 title claims abstract description 38
- 238000004393 prognosis Methods 0.000 title claims abstract description 29
- 238000011156 evaluation Methods 0.000 title claims abstract description 15
- 238000002626 targeted therapy Methods 0.000 title claims abstract description 13
- 230000004663 cell proliferation Effects 0.000 claims abstract description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 10
- 108020004459 Small interfering RNA Proteins 0.000 claims description 8
- 108010087230 Sincalide Proteins 0.000 claims description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical group C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims description 3
- 238000010370 cell cloning Methods 0.000 claims 1
- 229940124160 Myc inhibitor Drugs 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 8
- 230000035755 proliferation Effects 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 25
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 12
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000004055 small Interfering RNA Substances 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 238000003197 gene knockdown Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000010837 poor prognosis Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000447 dimerizing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
Abstract
The invention relates to an application of detecting transcription factor MAX gene expression quantity in a liver cancer c-MYC targeted therapy prognosis evaluation kit, belonging to the field of biotechnology, and mainly characterized in that prognosis of a patient with high expression MAX liver cancer is worse; the knockdown of MAX gene expression obviously inhibits the proliferation capacity of liver cancer cells; after the MAX gene is knocked down for 24 hours, a c-MYC inhibitor (the concentration is 100 mu M) is added, the cell proliferation capacity is obviously inhibited, and the expression level of the transcription factor MAX gene is detected, so that the curative effect of the c-MYC inhibitor on liver cancer is enhanced, the c-MYC inhibitor is used for predicting the prognosis of liver cancer c-MYC targeted therapy, and the method is simple, convenient and easy to implement.
Description
Technical Field
The invention relates to application of detecting transcription factor MAX gene expression quantity in liver cancer prognosis evaluation and c-MYC targeted therapy prognosis evaluation kit, belonging to the field of biotechnology, in particular to clinical detection technology.
Background
Hepatocellular carcinoma (hepatocellular carcinoma, HCC) is a common cancer with high morbidity and mortality, and is one of the cancers with the highest recurrence rate.
Liver cancer occurs involving accumulation of various genetic and epigenetic changes, including overexpression of the C-MYC gene due to amplification of the region in which the C-MYC gene is located. However, so far, no better targeting drug is available for treating liver cancer, which results in poor treatment effect and poor prognosis of patients. The c-MYC inhibitor is expected to be a target drug for treating liver cancer. In addition, liver cancer is a highly heterogeneous disease, and causes of different patients are different, so that diagnosis and treatment are different. Especially on different genetic bases, may cause differences in the therapeutic effects of chemotherapy drugs in patients. At present, no technical means for effectively carrying out prognosis judgment on the difference of the therapeutic effects of the chemotherapeutic drugs exists at home and abroad.
Establishing an effective postoperative prognosis prediction marker and exploring chemotherapy drug resistance related molecules has important significance for confirming which patients possibly have recurrence and metastasis after operation and carrying out postoperative radiotherapy and chemotherapy treatment in time, and which patients can resist chemotherapy and need to select individuation treatment (such as molecular targeting treatment).
Disclosure of Invention
Technical problems: the invention aims to provide the application of detecting the expression quantity of the transcription factor MAX gene in the liver cancer c-MYC targeted therapy prognosis evaluation kit aiming at liver cancer, thereby being capable of monitoring the prognosis situation of a liver cancer patient and leading the patient to be able to visit in time; meanwhile, an individuation treatment scheme is appointed by utilizing a prognosis evaluation result, targeted drugs are reasonably applied, ineffective targeted drug treatment is avoided, and the survival time of a patient is effectively prolonged.
In order to achieve the aim of the invention, the invention discloses application of detecting the expression quantity of the transcription factor MAX gene in a liver cancer c-MYC targeted therapy prognosis evaluation kit.
The technical scheme is as follows:
the application of detecting the expression quantity of the transcription factor MAX gene in the liver cancer c-MYC targeted therapy prognosis evaluation kit.
Further, the detection reagent consists of an antibody kit for transcription factor MAX gene expression, an siRNA interference sequence of MAX gene, a cell proliferation experiment kit for cell clone formation and the like.
Further, the kit consists of a monoclonal antibody, an HRP-labeled secondary antibody and a DAB color reagent which is a histochemical kit, wherein the monoclonal antibody is a MAX monoclonal antibody and/or MAX polyclonal antibody and a CCK-8 proliferation experiment detection kit.
Further, the biological sample of liver cancer is liver cancer operation tissue specimen, formalin fixed and/or paraffin embedded liver cancer tissue.
The beneficial effects are that:
because the expression level of the transcription factor MAX gene of the hepatocellular carcinoma patient is related to the pathological state and prognosis of the patient, the high expression of the transcription factor MAX gene in the hepatocellular carcinoma patient can be used as an independent risk factor for poor prognosis of the hepatocellular carcinoma. The expression level of the gene of the patient can be detected to guide the clinical establishment of an individualized chemotherapy scheme, so that the curative effect is improved. The advantage is that the high expression MAX prognosis of patients is poor, and effective targeting drugs are needed, if targeting drugs targeting c-MYC are used, the sensitivity of the c-MYC targeting drugs is improved by interfering with MAX gene expression so as not to use the drugs in an ineffective way.
Because MYC and Max form MYC/Max dimerizing small molecules that have oncogenic activity, MYC activity can be controlled by small molecules that interfere with both dimerization. Therefore, the MAX gene expression is knocked down, the dimerization of MYC/MAX is destroyed, and the oncogenic activity of MYC is relieved, thereby achieving the effect of tumor and liver cancer.
After the technical scheme disclosed by the invention is adopted, the expression level of the MAX gene can be detected by predicting the prognosis of liver cancer and utilizing an immunohistochemical technology, the expression level of the transcription factor MAX gene is knocked down by utilizing an siRNA interference experiment and is used in combination with a c-MYC inhibitor, so that the prognosis of a liver cancer patient after treatment by a liver cancer c-MYC targeted drug is predicted, the knocking-down mode of the transcription factor MAX gene is simple, the whole prediction evaluation is simple, convenient and easy, and the feasibility is high.
Drawings
FIG. 1 shows that a liver cancer patient with high expression of MAX gene has poor prognosis.
FIG. 2 shows the inhibition efficiency of small interfering RNA (siRNA) inhibiting MAX gene on MAX gene expression.
FIG. 3 shows that the proliferation capacity of liver cancer cells is obviously reduced after the expression of the MAX gene of the transcription factor is knocked down.
FIG. 4 shows that the sensitivity of liver cancer cells to treatment with C-MYC inhibitors is significantly enhanced after the MAX gene expression level is knocked down.
Detailed Description
For a better understanding of the present invention, we will further describe the present invention with reference to specific examples and drawings, but it should be noted that the practice of the present invention is not limited thereto.
The reagents and starting materials used in the present invention are commercially available or may be prepared according to literature procedures. The test methods of the specific conditions not specified in the examples of the present invention were all according to the conventional conditions or according to the conditions recommended by the manufacturer.
Example 1: relationship between MAX gene expression level and liver cancer prognosis
Immunohistochemical experimental detection is carried out on the expression level of the transcription factor MAX gene in the tissue of the hepatocellular carcinoma patient, wherein negative, false positive and weak positive are low expression groups, positive and strong positive are high expression groups, and the correlation between the low expression level and the high expression level of the transcription factor MAX gene and prognosis is analyzed according to Kaplan-Meier (KM), and the result is shown in figure 1. FIG. 1 shows the correlation between the relative expression level of the transcription factor MAX gene in the tissue chip of a patient with hepatocellular carcinoma and the prognosis of the patient. The patient with cancer tissue low expression transcription factor MAX gene has long life.
Example 2: experimental method for knocking down transcription factor MAX gene by adopting cell transfection
1. Adherent cells (liver cancer cells) were planted 1 day in advance: cells were seeded one day in advance in 24-well plates, preferably at about 30% confluency of cells at the time of transfection, and the total amount of medium before transfection was 0.45ml.
2. 0.67. Mu.g (50 pmol) of siRNA was added to a serum-free dilution and mixed well to a final volume of 25ml.
3. 1ml of Entranster-R4000 was taken, followed by addition of 24ml of serum-free dilution, and thoroughly mixing to give an Entranster-R4000 dilution having a final volume of 25ml. Standing at room temperature for 5 minutes.
4. The Entranster-R4000 dilution and the RNA dilution were mixed thoroughly (shaking with a shaker or sucking with a sample applicator for more than 10 times) and allowed to stand at room temperature for 15 minutes. The preparation of the transfection complex is completed.
5. Mu.l of the transfection complex was added dropwise to cells in 0.45ml of whole medium (which may contain 10% serum and antibiotics), the dishes were moved back and forth, and mixed well.
6. Cell status is observed 6 hours after transfection, if the cell status is good, the culture medium can not be replaced, and the cell transcription factor MAX gene expression level can be detected by continuing to culture for 24-96 hours.
The detection results are as follows:
FIG. 2 shows knockdown efficiency of MAX-siRNA interference sequences; after knocking down the transcription factor MAX gene of the siRNA interference sequence, the expression level of the transcription factor MAX gene is obviously reduced. (paired t-test, double tail, < P0.05, < P0.01, < P0.001).
Fig. 3 is an in vitro experiment: the cell proliferation capacity is reduced after the transcription factor MAX gene is knocked down. The CCK-8 cell proliferation detection kit is used for operation according to the description, and the light absorption value of the detection enzyme-linked immunosorbent assay is measured at the wavelength of 450nm, so that the number of living cells can be indirectly reflected. The lower the OD value, the lower the cell proliferation capacity. (paired t-test, double tail, < P0.05, < P0.01, < P0.001).
The detection kit is used for prognosis judgment of hepatocellular carcinoma by the following steps: (a) Detecting the expression level of the transcription factor MAX gene in the biological sample, (b) dividing the result into two types of high expression and low expression (or non-expression) according to the expression level of the transcription factor MAX gene detected in (a), (1) patients with high expression of the transcription factor MAX gene: the expression level of the transcription factor MAX gene of the hepatocellular carcinoma tissue of the patient is high, and the prognosis is lower than that of the patient with low expression. (2) transcription factor MAX Gene non/under-expression patient: the expression level of the transcription factor MAX gene of the hepatocellular carcinoma tissue of the patient is low, and the prognosis is good for the patient with higher expression. The patient should be closely followed up, and the corresponding tumor indications should be reviewed in time.
As used herein, low expression refers to negative, false positive and weak positive, and high expression refers to positive and strong positive.
In the invention, we disclose siRNA sequences that inhibit the expression of transcription factor MAX genes and their inhibition of growth of hepatocellular carcinoma cells.
The sequence is an interfering RNA sequence used for inhibiting expression of a transcription factor MAX gene in tumor cells, and belongs to RNA sequences (artificial sequences).
Example 3: experimental method for knocking down transcription factor MAX gene by adopting cell transfection
We examined the effect of MYC inhibitor 10058-F4 on the proliferative capacity of MHCC97H cells in constructed MAX-knock down MHCC97H cells. And (3) detecting by using a CCK-8 kit, and drawing a growth curve of MHCC97H cells according to the detection result. The result shows that after the MAX gene is knocked down for 24 hours, the growth trend of liver cancer cells starts to be different, and the MYC inhibitor (with the concentration of 100 mu M) is added at the moment, so that the difference of the proliferation capability of the cells is more obvious. Compared with the cells of the control group, the MYC inhibitor can effectively inhibit the proliferation capability of MHCC97H cells, has statistical difference, and the knock-down of MAX gene expression obviously improves the proliferation inhibition capability of the MYC inhibitor on liver cancer cells (shown in figure 4). The experimental results show that after the MAX gene is knocked down in liver cancer cells, the proliferation inhibition effect of MYC inhibitor on the liver cancer cells is obviously enhanced, which suggests that inhibiting the MAX gene expression in liver cells can enhance the curative effect of MYC inhibitor on tumor treatment.
The above embodiments are only preferred embodiments of the present invention, and should not be construed as limiting the present invention, and the protection scope of the present invention should be defined by the claims, including the technical equivalents of the technical features in the claims, as the protection scope, that is, the equivalent replacement and improvement within the protection scope of the present invention.
<110> university of southeast medical college
<120> application of detecting transcription factor MAX gene expression quantity in liver cancer c-MYC targeted therapy prognosis evaluation kit
<160> 2
<210> 1
<211> 21
<212> DNA
<213> artificial sequence
<400> 1
GAGCAACCGA GGUUUCAAUT T 21
<210> 2
<211> 21
<212> DNA
<213> artificial sequence
<400> 2
AUUGAAACCU CGGUUGCUCT T 21
Claims (4)
1. The application of the reagent for detecting the expression level of the transcription factor MAX gene in preparing a liver cancer c-MYC targeted therapy prognosis evaluation kit.
2. The use of a reagent for detecting the expression level of transcription factor MAX gene according to claim 1 in preparing a kit for prognosis evaluation of liver cancer c-MYC targeted therapy, wherein the detection reagent consists of a transcription factor MAX gene siRNA interference sequence and a cell proliferation experimental reagent formed by cell cloning.
3. The use of the reagent for detecting the expression level of transcription factor MAX gene according to claim 2 in preparing a liver cancer c-MYC targeted therapy prognosis evaluation kit, characterized in that the reagent kit is a CCK-8 reagent kit.
4. The use of the reagent for detecting transcription factor MAX gene expression level according to claim 1 in preparing a liver cancer c-MYC targeted therapy prognosis evaluation kit, wherein the biological sample of liver cancer is a liver cancer surgical tissue specimen, formalin-fixed or paraffin-embedded liver cancer tissue.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110901877.8A CN113607946B (en) | 2021-08-06 | 2021-08-06 | Application of detecting transcription factor MAX gene expression quantity in liver cancer c-MYC targeted therapy prognosis evaluation kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110901877.8A CN113607946B (en) | 2021-08-06 | 2021-08-06 | Application of detecting transcription factor MAX gene expression quantity in liver cancer c-MYC targeted therapy prognosis evaluation kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113607946A CN113607946A (en) | 2021-11-05 |
| CN113607946B true CN113607946B (en) | 2023-12-08 |
Family
ID=78339681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110901877.8A Active CN113607946B (en) | 2021-08-06 | 2021-08-06 | Application of detecting transcription factor MAX gene expression quantity in liver cancer c-MYC targeted therapy prognosis evaluation kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113607946B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103687963A (en) * | 2011-07-12 | 2014-03-26 | 小利兰·斯坦福大学理事会 | A method of determining the prognosis of hepatocellular carcinomas using a multigene signature associated with metastasis |
| CN111172283A (en) * | 2020-02-18 | 2020-05-19 | 东南大学 | Application of detecting linc00673 expression quantity in esophageal cancer targeted therapy prognosis evaluation kit |
| CN111308074A (en) * | 2019-12-12 | 2020-06-19 | 中山大学附属第三医院 | Application of diagnosis marker for detecting hepatocellular carcinoma and screening or auxiliary diagnosis product |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2742138B1 (en) * | 2011-08-09 | 2020-06-24 | Fred Hutchinson Cancer Research Center | Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells |
-
2021
- 2021-08-06 CN CN202110901877.8A patent/CN113607946B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103687963A (en) * | 2011-07-12 | 2014-03-26 | 小利兰·斯坦福大学理事会 | A method of determining the prognosis of hepatocellular carcinomas using a multigene signature associated with metastasis |
| CN111308074A (en) * | 2019-12-12 | 2020-06-19 | 中山大学附属第三医院 | Application of diagnosis marker for detecting hepatocellular carcinoma and screening or auxiliary diagnosis product |
| CN111172283A (en) * | 2020-02-18 | 2020-05-19 | 东南大学 | Application of detecting linc00673 expression quantity in esophageal cancer targeted therapy prognosis evaluation kit |
Non-Patent Citations (3)
| Title |
|---|
| c-myc在肝细胞肝癌中的表达及其临床意义;王少军;赵屹;张峰;姜超;邹奇飞;;实用临床医药杂志(第07期);全文 * |
| 原发性肝癌中Survivin mRNA的定量表达及其临床意义;浦涧;汪建初;李良波;韦忠恒;陆涛;马燕飞;覃志坚;;广东医学(第04期);全文 * |
| 胡少辉 ; 张志伟 ; 陈孝平 ; .skp2,C-myc在肝细胞肝癌中的表达及其意义.中国普通外科杂志.2006,(第01期),全文. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113607946A (en) | 2021-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Deubiquitinase activity profiling identifies UCHL1 as a candidate oncoprotein that promotes TGFβ-induced breast cancer metastasis | |
| Ryu et al. | Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced cell migration | |
| Chen et al. | CSTF2-induced shortening of the RAC1 3′ UTR promotes the pathogenesis of urothelial carcinoma of the bladder | |
| Deng et al. | Parathyroid hormone-related protein and ezrin are up-regulated in human lung cancer bone metastases | |
| US20230366035A1 (en) | Biomarker for her2-positive cancer and anti-her2 therapy and applications thereof | |
| Jiang et al. | High expression of NSUN5 promotes cell proliferation via cell cycle regulation in colorectal cancer | |
| JP2019150027A (en) | Methods and compositions for predicting response to eribulin | |
| JP4851451B2 (en) | Breast cancer-related gene ZNFN3A1 | |
| Li et al. | USP22 drives colorectal cancer invasion and metastasis via epithelial-mesenchymal transition by activating AP4 | |
| Yu et al. | AEG-1 contributes to metastasis in hypoxia-related ovarian cancer by modulating the HIF-1alpha/NF-kappaB/VEGF pathway | |
| Chen et al. | LncRNA GAPLINC promotes the growth and metastasis of glioblastoma by sponging miR-331-3p. | |
| Gong et al. | Upregulated LINC00565 accelerates ovarian cancer progression by targeting GAS6 | |
| Chen et al. | The predictive role of E2-EPF ubiquitin carrier protein in esophageal squamous cell carcinoma | |
| Zhang et al. | GNG5 is a novel oncogene associated with cell migration, proliferation, and poor prognosis in glioma | |
| CN111172283B (en) | Application of detecting linc00673 expression quantity in esophageal cancer targeted therapy prognosis evaluation kit | |
| KR101596166B1 (en) | A Use of microRNA for Ddiagnosing and Treating Brest Cancer | |
| Lin et al. | Nucleophosmin/B23 promotes endometrial cancer cell escape from macrophage phagocytosis by increasing CD24 expression | |
| CN113607946B (en) | Application of detecting transcription factor MAX gene expression quantity in liver cancer c-MYC targeted therapy prognosis evaluation kit | |
| Kaira et al. | Prognostic and predictive factors in resected non-small-cell lung cancer | |
| US10881677B2 (en) | Composition for modulating IRAK1 | |
| Maleki et al. | LINK-A long non-coding RNA and VEGF RNA expression in epithelial ovarian cancer patients | |
| CN112114143B (en) | Application of hepatoma diagnosis and cancer-causing kinase treatment marker | |
| Eryi et al. | HOXC6 Regulates the Epithelial-Mesenchymal Transition through the TGF-β/Smad Signaling Pathway and Predicts a Poor Prognosis in Glioblastoma | |
| CN110777204B (en) | Application of MAFG-AS1 knock-out reagent in preparation of medicines for treating bladder cancer | |
| Liang et al. | MiR-205 inhibits the invasion and migration of esophageal squamous cell carcinoma by modulating SMAD1 expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |